Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma:
Final Analysis of the German Hodgkin Study Group HD14 Trial

J 2012

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

VON TRESCKOW, Bastian, Annette PLUETSCHOW, Michael FUCHS, Beate KLIMM, Jana MARKOVA et. al.

Základní údaje

Originální název

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

Autoři

VON TRESCKOW, Bastian (276 Německo, garant), Annette PLUETSCHOW (276 Německo), Michael FUCHS (276 Německo), Beate KLIMM (276 Německo), Jana MARKOVA (203 Česká republika), Andreas LOHRI (756 Švýcarsko), Zdeněk KRÁL (203 Česká republika, domácí), Richard GREIL (40 Rakousko), Max S. TOPP (276 Německo), Julia MEISSNER (276 Německo), Josee M. ZIJLSTRA (528 Nizozemské království), Martin SOEKLER (276 Německo), Harald STEIN (276 Německo), Hans T. EICH (276 Německo), Rolf P. MUELLER (276 Německo), Volker DIEHL (276 Německo), Peter BORCHMANN (276 Německo) a Andreas ENGERT (276 Německo)

Vydání

Journal of Clinical Oncology, United States, American Society of Clinical Oncology, 2012, 0732-183X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 18.038

Kód RIV

RIV/00216224:14110/12:00060735

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1200/JCO.2011.38.5807

UT WoS

000302628400008

Klíčová slova anglicky

INVOLVED-FIELD RADIOTHERAPY; NODE RADIOTHERAPY; CHEMOTHERAPY; DISEASE; PROGRESSION; INTENSITY; RADIATION; SURVIVAL; CYCLES

Příznaky

Mezinárodní význam

Změněno: 4. 9. 2012 13:15, Mgr. Michal Petr

Anotace

V originále

Purpose In patients with early unfavorable Hodgkin's lymphoma (HL), combined modality treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field radiotherapy (IFRT) results in long-term tumor control of approximately 80%. We aimed to improve these results using more intensive chemotherapy. Patients and Methods Patients with newly diagnosed early unfavorable HL were randomly assigned to either four cycles of ABVD or an intensified treatment consisting of two cycles of escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) followed by two cycles of ABVD (2 + 2). Chemotherapy was followed by 30 Gy IFRT in both arms. The primary end point was freedom from treatment failure (FFTF); secondary end points included progression-free survival (PFS) and treatment-related toxicity. Results With a total of 1,528 qualified patients included, the 2 + 2 regimen demonstrated superior FFTF compared with four cycles of ABVD (P < .001; hazard ratio, 0.44; 95% CI, 0.30 to 0.66), with a difference of 7.2% at 5 years (95% CI, 3.8 to 10.5). The difference in 5-year PFS was 6.2% (95% CI, 3.0% to 9.5%). There was more acute toxicity associated with 2 + 2 than with ABVD, but there were no overall differences in treatment-related mortality or secondary malignancies. Conclusion Intensified chemotherapy with two cycles of BEACOPP escalated followed by two cycles of ABVD followed by IFRT significantly improves tumor control in patients with early unfavorable HL.

Citovat

VON TRESCKOW, Bastian, Annette PLUETSCHOW, Michael FUCHS, Beate KLIMM, Jana MARKOVA, Andreas LOHRI, Zdeněk KRÁL, Richard GREIL, Max S. TOPP, Julia MEISSNER, Josee M. ZIJLSTRA, Martin SOEKLER, Harald STEIN, Hans T. EICH, Rolf P. MUELLER, Volker DIEHL, Peter BORCHMANN a Andreas ENGERT. Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. Journal of Clinical Oncology. United States: American Society of Clinical Oncology, 2012, roč. 30, č. 9, s. 907-913. ISSN 0732-183X. Dostupné z: https://dx.doi.org/10.1200/JCO.2011.38.5807.

@article{990828,
   author = {von Tresckow, Bastian and Pluetschow, Annette and Fuchs, Michael and Klimm, Beate and Markova, Jana and Lohri, Andreas and Král, Zdeněk and Greil, Richard and Topp, Max S. and Meissner, Julia and Zijlstra, Josee M. and Soekler, Martin and Stein, Harald and Eich, Hans T. and Mueller, Rolf P. and Diehl, Volker and Borchmann, Peter and Engert, Andreas},
   article_location = {United States},
   article_number = {9},
   doi = {http://dx.doi.org/10.1200/JCO.2011.38.5807},
   keywords = {INVOLVED-FIELD RADIOTHERAPY; NODE RADIOTHERAPY; CHEMOTHERAPY; DISEASE; PROGRESSION; INTENSITY; RADIATION; SURVIVAL; CYCLES},
   language = {eng},
   issn = {0732-183X},
   journal = {Journal of Clinical Oncology},
   title = {Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial},
   volume = {30},
   year = {2012}
}

TY  - JOUR
ID  - 990828
AU  - von Tresckow, Bastian - Pluetschow, Annette - Fuchs, Michael - Klimm, Beate - Markova, Jana - Lohri, Andreas - Král, Zdeněk - Greil, Richard - Topp, Max S. - Meissner, Julia - Zijlstra, Josee M. - Soekler, Martin - Stein, Harald - Eich, Hans T. - Mueller, Rolf P. - Diehl, Volker - Borchmann, Peter - Engert, Andreas
PY  - 2012
TI  - Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
JF  - Journal of Clinical Oncology
VL  - 30
IS  - 9
SP  - 907-913
EP  - 907-913
PB  - American Society of Clinical Oncology
SN  - 0732183X
KW  - INVOLVED-FIELD RADIOTHERAPY
KW  - NODE RADIOTHERAPY
KW  - CHEMOTHERAPY
KW  - DISEASE
KW  - PROGRESSION
KW  - INTENSITY
KW  - RADIATION
KW  - SURVIVAL
KW  - CYCLES
N2  - Purpose In patients with early unfavorable Hodgkin's lymphoma (HL), combined modality treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field radiotherapy (IFRT) results in long-term tumor control of approximately 80%. We aimed to improve these results using more intensive chemotherapy. Patients and Methods Patients with newly diagnosed early unfavorable HL were randomly assigned to either four cycles of ABVD or an intensified treatment consisting of two cycles of escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) followed by two cycles of ABVD (2 + 2). Chemotherapy was followed by 30 Gy IFRT in both arms. The primary end point was freedom from treatment failure (FFTF); secondary end points included progression-free survival (PFS) and treatment-related toxicity. Results With a total of 1,528 qualified patients included, the 2 + 2 regimen demonstrated superior FFTF compared with four cycles of ABVD (P < .001; hazard ratio, 0.44; 95% CI, 0.30 to 0.66), with a difference of 7.2% at 5 years (95% CI, 3.8 to 10.5). The difference in 5-year PFS was 6.2% (95% CI, 3.0% to 9.5%). There was more acute toxicity associated with 2 + 2 than with ABVD, but there were no overall differences in treatment-related mortality or secondary malignancies. Conclusion Intensified chemotherapy with two cycles of BEACOPP escalated followed by two cycles of ABVD followed by IFRT significantly improves tumor control in patients with early unfavorable HL.
ER  -

VON TRESCKOW, Bastian, Annette PLUETSCHOW, Michael FUCHS, Beate KLIMM, Jana MARKOVA, Andreas LOHRI, Zdeněk KRÁL, Richard GREIL, Max S. TOPP, Julia MEISSNER, Josee M. ZIJLSTRA, Martin SOEKLER, Harald STEIN, Hans T. EICH, Rolf P. MUELLER, Volker DIEHL, Peter BORCHMANN a Andreas ENGERT. Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. \textit{Journal of Clinical Oncology}. United States: American Society of Clinical Oncology, 2012, roč.~30, č.~9, s.~907-913. ISSN~0732-183X. Dostupné z: https://dx.doi.org/10.1200/JCO.2011.38.5807.

Podrobný výpis o publikaci